Therapeutics and Clinical Risk Management (Oct 2019)
Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
Abstract
Chin-Chou Huang,1–5 Min-Ji Charng2,3 1Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; 2Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3Faculty of Medicine, School of Medicine, National Yang–Ming University, Taipei, Taiwan; 4Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan; 5Institute of Pharmacology, National Yang-Ming University, Taipei, TaiwanCorrespondence: Min-Ji CharngDivision of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Taiwan, R. O. C.Tel +886 2 28757507Fax +886 2 28756849Email [email protected] HuangDepartment of Medical Education, Taipei Veterans General hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Taiwan, R. O. C.Tel +886 2 28757725Fax +886 2 28757726Email [email protected]: Evolocumab, which can lower low-density lipoprotein (LDL) cholesterol levels by approximately 60% and prevent cardiovascular events in patients with cardiovascular disease, is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Some studies have investigated its efficacy and safety in the treatment of the homozygous form of familial hypercholesterolemia (HoFH), and others have focused on its efficacy and safety in Asians with high cardiovascular risk. Although no direct evolocumab clinical trials have been conducted in Chinese HoFH patients, its efficacy and safety in the Chinese population should be similar to those in other ethnic groups.Keywords: Chinese, evolocumab, homozygous familial hypercholesterolemia, low-density lipoprotein, proprotein convertase subtilisin/kexin type 9
